Trends and Determinants in Mortality after Cirrhosis-Related Admissions over a Decade
AASLD LiverLearning®, Aylin Tansel, 144646
Primary Care and Hepatology Provider Attitudes Towards Hepatitis C Treatment Candidacy and Adherence
AASLD LiverLearning®, Shari Rogal, 144647
Bridging the gap: Facilitating linkage to care for persons identified with chronic hepatitis C infections through a public health program
AASLD LiverLearning®, Arlene Sena, 144648
Reduction in hemoglobin and Increased lab encounters among Veterans treated with ledipasvir-sofosbuvir combined with ribavirin
AASLD LiverLearning®, Lydia Tang, 144904
Impact of Pre-Existing Liver Disease on Treatment and Outcomes of Breast Cancer
AASLD LiverLearning®, Joseph Menzin, 144649
Effect of interferon free antiviral treatment on lipid metabolism, lipid oxidation and insulin-resistance in chronic hepatitis C patients with advanced liver disease
AASLD LiverLearning®, Elisa Biliotti, 144905
Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype 1a and NS5A Y93H variant in Genotype 3 for interferon-free treatment combinations with direct antiviral agents (DAAs): Real-life experience from a multicenter study in Sweden and Norway
AASLD LiverLearning®, Johan Lennerstrand, 144906
Balloon Tamponade Utilization is an Indicator of Quality in the Management of Acute Variceal Hemorrhage
AASLD LiverLearning®, Elliot Tapper, 144662
High incidence of significant liver fibrosis among HBeAg-positive patients with low levels of ALT
AASLD LiverLearning®, Milan Sonneveld, 144663
Transient Elastography in Assessment of Liver Fibrosis in Children with Chronic Hepatitis B: PEG-B-ACTIVE Liver Elasticity Substudy
AASLD LiverLearning®, Vedran Pavlovic, 144664
Clinically Significant Changes in Heart Rate and Adverse Events are Not Observed in Clinical Trial Patients Receiving SOF-Based Regimens While On Beta-Blockers
AASLD LiverLearning®, Curtis Cooper, 144920
Community-Based Strategies to Improve Testing and Linkage to Care for Foreign-Born Persons with Chronic Hepatitis B Virus Infection
AASLD LiverLearning®, Aaron Harris, 144665
Increase in 10-Year Framingham Cardiovascular Risk Following HCV Eradication with DAA-Based Therapy in HIV/HCV-Coinfected Patients
AASLD LiverLearning®, Teresa Aldámiz-Echevarría, 144921
Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients with Chronic HCV Infection and HIV/HCV Co-Infection
AASLD LiverLearning®, Vasily Isakov, 144922
Development and performance of prototype serologic and molecular tests for the detection and quantification of the hepatitis Delta virus on the Abbott ARCHITECT and m2000 instruments.
AASLD LiverLearning®, Gavin Cloherty, 144678
Glucocorticoid Pulse Therapy and Hepatitis B Flares: A Retrospective Cohort Study
AASLD LiverLearning®, Sheng-Shun Yang, 144679
Progression of initially mild hepatic fibrosis in Chronic hepatitis B patients: a prospective repeat liver biopsy study
AASLD LiverLearning®, Xiao ling Chi, 144680
Quick Sequential Organ Failure Assessment (qSOFA) is a Better Predictor for Intensive Care Admission than Systemic Inflammatory Response Syndrome (SIRS) For Patients with Cirrhosis
AASLD LiverLearning®, Kavish Patidar, 144936
Patients with HIV-HBV coinfection are an underestimated reservoir for Hepatitis Delta Virus. An analysis of the ICONA cohort
AASLD LiverLearning®, GIOVANNI B. GAETA, 144681
Does the presence of cirrhosis influence on the mortality rate in patients with acute on chronic liver failure?
AASLD LiverLearning®, Sombat Treeprasertsuk, 144937
Long-term prognosis of patients who survived from acute-on-chronic liver failure based on KACLiF cohort
AASLD LiverLearning®, Eileen Yoon, 144938
Prevention system of acute exacerbation of chronic hepatitis B infection in patients receiving chemotherapy and immunosuppressive therapy in Miyazaki, Japan
AASLD LiverLearning®, Yuuri Yamada, 144694
Preventing mother to child transmission of HBV in an ethnically diverse South London population: an effective multidisciplinary clinical pathway
AASLD LiverLearning®, Ivana Carey, 144695
Hepatitis B surface antigen (HBsAg) seroclearance, hepatocellular carcinoma (HCC) and liver-related death (LRD) risk among Alaska Native (AN) persons with indeterminate phase chronic hepatitis B virus infection (CHB) — Alaska, 2001-2014
AASLD LiverLearning®, Michael Bruce, 144696
NMR based urinary profiling of Lactulose/Mannitol ratio to compare the intestinal permeability in cirrhosis, acute on chronic liver failure (ACLF) patients and normal controls
AASLD LiverLearning®, Gaurav Pande, 144952
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay
AASLD LiverLearning®, Noboru Shinkai, 144697
Monocyte HLA-DR expression, neutrophil oxidative burst capacity and cytokine analysis in patients with decompensated cirrhosis with and without acute-on-chronic liver failure (ACLF).
AASLD LiverLearning®, Ajay Duseja, 144953
MELD-Na and SBP predict mortality in Refractory Ascites
AASLD LiverLearning®, Sanaa Ayyoub, 144954
Racial disparity in the Prevalence of Hepatitis B Virus (HBV) Infection in the United States: Results from the National Health and Nutrition Examination Survey 2011-2014
AASLD LiverLearning®, Hyunseok Kim, 144711
Subcirrhotic liver stiffness by transient elastography correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis
AASLD LiverLearning®, Mi Young Jeon, 144712
Comparison of prognostic efficacy of acute kidney injury criteria in patients with liver cirrhosis
AASLD LiverLearning®, Taehyung Kim, 144968
Male and hepatitis B infection are independent factors affecting patient’s compliance with surveillance of hepatocellular carcinoma
AASLD LiverLearning®, Satoshi Oeda, 144713
Patients with Refractory Ascites Treated with alfapump® System (AP) have Better Health-related Quality of Life (HRQL) as Compared to those Treated with Large Volume Paracentesis (LVP): Results of a Multicenter Randomized Controlled Study
AASLD LiverLearning®, Zobair Younossi, 144969
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort
AASLD LiverLearning®, Segolene Brichler, 144714
The Burden of Hepatorenal Syndrome among Commercially-Insured and Medicare Patients in the United States
AASLD LiverLearning®, Khurram Jamil, 144970
Validation of a diagnostic strategy combining the transient elastography liver stiffness value and enhanced liver fibrosis test to assess the fibrotic burden in patients with chronic hepatitis B
AASLD LiverLearning®, Ja Yoon Heo, 144727
Profile of viral, biochemical and non-invasive fibrosis markers in a cohort of inactive European hepatitis B (HBV) carriers: 3 years follow-up of a prospective longitudinal study (ALBATROS Study)
AASLD LiverLearning®, Viola Knop, 144728
Urine and Serum Biomarkers in Predicting Recovery of Renal Function After Liver Transplantation Among Patients with Cirrhosis and Pre-transplant Renal insufficiency: A Prospective Study
AASLD LiverLearning®, Ashwani Singal, 144984
Expression profile alterations of lncRNAs on the molecular pathogenesis of hepatitis B*
AASLD LiverLearning®, Sunde Yilmaz Susluer, 144729
Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial
AASLD LiverLearning®, Nina Kimer, 144985
Serum hepatitis B core-related antigen and surface antigen levels are correlated with hepatic fibrosis and inflammatory activity in treatment-naïve chronic hepatitis B patients
AASLD LiverLearning®, Tetsuya Hosaka, 144730
Rifaximin has limited effect on the inflammatory state and bacterial translocation in the patient with stable decompensated cirrhosis. Results from a randomized, placebo controlled trial.
AASLD LiverLearning®, Nina Kimer, 144986
Safety and Efficacy of GS-9620 in Virally-Suppressed Patients with Chronic Hepatitis B
AASLD LiverLearning®, Harry Janssen, 144743
Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B
AASLD LiverLearning®, Scott Fung, 144744
Hyperammonemia induces a novel maladaptive cellular stress response and impaired proteostasis resulting in sarcopenia.
AASLD LiverLearning®, Srinivasan Dasarathy, 145000
Low serum HBsAg level predicts HBsAg seroclearance and sustained response in chronic hepatitis B after stopping oral NUCs
AASLD LiverLearning®, Apinya Leerapun, 144745
The Multikinase-Inhibitor Regorafenib Improves Portal Hypertension In Presence And Absence Of Cirrhosis In Rats
AASLD LiverLearning®, Uschner Frank Erhard, 145001
The effects of non-alcoholic fatty liver disease on liver fibrosis in chronic hepatitis B patients on nucleoside analogue therapy: results from a matched-case control study.
AASLD LiverLearning®, Wai-Kay Seto, 144746
Antioxidant attenuates hyperdynamic circulation by mitigating mesenteric inflammation and nitric oxide production in cirrhotic rats
AASLD LiverLearning®, hongqun liu, 145002
The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients
AASLD LiverLearning®, George Papatheodoridis, 144759
TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells
AASLD LiverLearning®, Roland Kratzer, 144760
Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist
AASLD LiverLearning®, Joseph Grippo, 144761
A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144
AASLD LiverLearning®, Jinghang Xu, 144762
Pharmacokinetics (PK) and PK modeling of the first-in-class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients with chronic HBV infection (CHBV)
AASLD LiverLearning®, Thomas Kakuda, 144775
Risk of Renal Function Impairment Among Cancer Patients Treated With Tenofovir or Entecavir for HBV Prophylaxis During Chemotherapy
AASLD LiverLearning®, Yi-Hsiang Huang, 144776
Pharmacokinetics, Safety and Antiviral Activity of CMX157, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects
AASLD LiverLearning®, John Sullivan-Bolyai, 144778
Post-treatment dynamic changes of liver stiffness to predict first 2-year outcomes in HBV compensated cirrhosis
AASLD LiverLearning®, Hong You, 144779
The Effect of a 12-month Weight Loss Program on Non-alcoholic Fatty Liver Disease in Obese Patients
AASLD LiverLearning®, Anna Hefner, 144535
Limited Real-World Provider Prescription of 8 week LDV/SOF Regimen: A potential barrier in widespread treatment access
AASLD LiverLearning®, Chloe Gross, 144536
HBV RNA and HBV core-related antigen (HBcrAg) are early serum markers for HBeAg seroconversion in treatment experienced patients receiving tenofovir disoproxil fumarate (TDF)-containing regimens
AASLD LiverLearning®, Florian van Boemmel, 144792
Introducing the Australasian Hepatology Association’s Consensus Guidelines for the Provision of Adherence Support to People with Hepatitis C taking Direct Acting Antivirals
AASLD LiverLearning®, Jacqueline Richmond, 144537
Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
AASLD LiverLearning®, Young-Suk Lim, 144793
Baseline Quantitative Hepatitis B Core Antibody Level strongly Predicts 240-week Treatment Response in HBeAg-positive Chronic Hepatitis B Patients Receiving Entecavir
AASLD LiverLearning®, Jinghang Xu, 144794
Elevated WFA+M2BP, ALT flare and HBs decline>1.0Log/ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients
AASLD LiverLearning®, Miwa Kawanaka, 144795
Regional and National understanding of IgG-related disease (IgG4-RD) in the UK- strategic implications in testing and case-finding
AASLD LiverLearning®, Marinos Pericleous, 144551
JKB-122 is Effective, Alone or in Combination with Prednisolone in Con A-induced Hepatitis, a Model for Autoimmune Hepatitis.
AASLD LiverLearning®, May Mei-Chi HSU, 144552
Using telemedicine to monitor patients on treatment of HCV infection in prison
AASLD LiverLearning®, Javier Crespo, 144808
Frequency of CCR7-PD-1+ follicular helper T cell subset as a possible diagnostic marker of autoimmune hepatitis
AASLD LiverLearning®, Satoshi Yamagiwa, 144553
Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments
AASLD LiverLearning®, Behzad Hajarizadeh, 144809
Metabolic syndrome, hepatic steatosis and genotype 1b C virus compensated liver cirrhosis in the era of Direct Acting Antiviral therapy
AASLD LiverLearning®, Catalina Mihai, 144810
High mobility group box-1 participates in the pathogenesis of liver fibrosis
AASLD LiverLearning®, Xiaodong Ge, 144567
A novel murine model to deplete HSCs from normal liver with GFP-specific CD8+ T cells
AASLD LiverLearning®, Takuma Tsuchida, 144568
Virological response to ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin in 150 patients with mixed cryoglobulinaemia and HCV infection
AASLD LiverLearning®, Liana Gheorghe, 144824
Bioinformatic Identification and Validation of C1QTNF2 as a Candidate Antifibrotic Molecule in Hepatic Stellate Cells
AASLD LiverLearning®, Daniel Hicks, 144569
Treatment of Patients with Hepatitis C Virus infection (Genotype 4) with Ledipasvir-Sofosbuvir in the liver transplant setting
AASLD LiverLearning®, Faisal Abaalkhail, 144825
Genotype 3 Infection In DAA Era: Preliminary Reports Of a Real Life Northern Italy Network For Viral Hepatitis
AASLD LiverLearning®, pasulo luisa, 144826
MMP9 is a potential mediator of TWEAK-Fn14 signaling in a rodent model of acute alcoholic steatohepatitis
AASLD LiverLearning®, Anna Mae Diehl, 144583
Loss of retinaldehyde dehydrogenase 1 enzymatic function attenuates liver fibrosis in a murine model of cirrhosis
AASLD LiverLearning®, Loretta Jophlin, 144584
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis HCV genotype 1b infection in patients with severe fibrosis; From real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144840
Correlation of Cytoglobin Level in Stellate Cells with Promotion or Attenuation of Liver Fibrosis and Cancer in Mice
AASLD LiverLearning®, Thuy Le, 144585
Effectiveness of Sofosbuvir/Ledipasvir HCV Treatment Regimens in a Community Setting
AASLD LiverLearning®, T Craig Cheetham, 144841
Glyco-isomer of serum Mac-2-binding protein (M2BPGi) were dramatically decreased due to anti-viral therapy in chronic hepatitis C (CHC) patients
AASLD LiverLearning®, Mina Hamano, 144842
Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Baveno VI criteria and beyond
AASLD LiverLearning®, Roberta D Ambrosio, 144599
Management Of Refractory Variceal Bleed With Dannis-Ella Stent In Patients With Acute On Chronic Liver Failure
AASLD LiverLearning®, RAKHI MAIWALL, 144600
Interferon-free therapies on routine medical practice for the treatment of hepatitis C infection in difficult to treat HIV coinfected patients: results of the multicentric COINFECOVA-2 study.
AASLD LiverLearning®, Carlos Minguez, 144856
Vibration-Controlled Transient Elastography (VCTE) is Useful in Identifying Clinically Significant Portal Hypertension in Patients with NASH Cirrhosis
AASLD LiverLearning®, Raj Vuppalanchi, 144601
Treatment of Chronic Hepatitis C Genotype 4 -infected Patients with Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin: Real Life Data From Saudi Arabia
AASLD LiverLearning®, khalid alswat, 144857
Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin Pharmacokinetics in HCV-Infected Subjects with Chronic Kidney Disease Stage 4 (Severe Renal Impairment) or Stage 5 (End-Stage Renal Disease)
AASLD LiverLearning®, Diana Shuster, 144858
Hepatitis C Treatment in United States Prisons Prevents Transmission and is Cost-Saving for the Society
AASLD LiverLearning®, Jag Chhatwal, 144615
Ledipasvir/Sofosbuvir (LDV/SOF) treatment of naïve patients with mild chronic hepatitis C (CHC) genotype 1 (GT1) compared to patients with significant fibrosis: is it a cost-effective therapy?
AASLD LiverLearning®, Maria Buti, 144616
DAA-Treatment of HCV-infected patients on Opioid Substitution Therapy (OST): does the clinical setting matter? Data from the German Hepatitis C-Registry (DHC-R)
AASLD LiverLearning®, Stefan Christensen, 144872
Hepatitis E infection in a large cohort of solid organ and stem cell recipients prior to transplantation
AASLD LiverLearning®, Jordi Llaneras Artigues, 144617
Safety and efficacy of regimens including direct acting antivirals (DAAs) in chronic hepatitis C (CHC) patients over the age of 70 years
AASLD LiverLearning®, Emmanouil Sinakos, 144873
Effectiveness of hcv antiviral treatment in patients with cirrhosis or advanced fibrosis and end-stage kidney disease on dialysis
AASLD LiverLearning®, Francesca Romana Ponziani, 144874
Hospital re-admission predicts 5-year survival in patients with cirrhosis - A population-based study.
AASLD LiverLearning®, Jennifer Flemming, 144631
Outpatient primary care physician utilization before and after index hospitalization in patients with decompensated liver cirrhosis enrolled in a large national health insurance administrative database
AASLD LiverLearning®, Steven Scaglione, 144632
Sofosbuvir/Ledipasvir in the Treatment of Early HCV Infection in HIV-infected Men
AASLD LiverLearning®, Daniel Fierer, 144888
Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities
AASLD LiverLearning®, George Cholankeril, 144633
Primary care based model using patient navigators highly successful in obtaining HCV medications for inner-city HCV-monoinfected patients
AASLD LiverLearning®, Wilma Toribio, 144889
chronic hepatitis c treatment with new generation direct-acting antivirals - real-life data from a portuguese center
AASLD LiverLearning®, LURDES SANTOS, 144890